Mirati Therapeutics Revenue, Growth & Competitor Profile

DBA MIRATI

Company Profile & Annual Report for Mirati Therapeutics

Access the complete profile.

Mirati Therapeutics Fast Facts

Revenue	$100 - $500 million    See Exact Annual Revenue
Employees	500 - 1,000Exact Company Size
Primary Industry	5417 Scientific Research & Development Services
Address	3545 Cray Ct San Diego, CA 92121

Mirati Therapeutics's Annual Report & Profile shows critical firmographic facts:

• What is the company's size? (Annual sales and employees)
  • Mirati Therapeutics's annual revenues are $100 - $500 million (see exact revenue data)
• What industry is the company in?
  • Mirati Therapeutics is classified as operating in the Scientific Research & Development Services industry, NAICS Code 5417.

Mirati Therapeutics is a publicly traded company on NMS using the ticker symbol MRTX. Detailed information on company financials and operating reports can be found here: NMS: MRTX

Mirati Therapeutics Annual Revenue and Growth Rate

Mirati Therapeutics	Revenue Est. ($ Million)	Growth Rate (%)	# Employees
2023	$100 - $500 million Details in Premium Report
2022
2021
2020
2019

1-Year Growth Rate: 3-Year Growth Rate (CAGR):

Note: Mirati Therapeutics's revenues are gauged from an analysis of company filings.

Trademark Applications

Trademark applications show the products and services that Mirati Therapeutics is developing and marketing. Mirati Therapeutics's new tradmarks suggest it is investing in R&D and marketing, while expanding into new products or markets. Trademarks may include brand names, product names, logos and slogans.

Trademark	Date
STRA Pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for use in oncology; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for the treatment of lung cancer; pharmaceutical preparations for the treatment of non-small cell lung carcinoma; pharmaceutical preparations for the treatment of colorectal carcinoma; pharmaceutical preparations for the treatment of pancreatic cancer; pharmaceuticals comprising small molecules for the treatment of cancer; pharmaceuticals comprising small molecules for the treatment of infectious diseases; pharmaceuticals comprising small molecules for the treatment of lung cancer; pharmaceuticals comprising small molecules for the treatment of non-small cell lung carcinoma; pharmaceuticals comprising small molecules for the treatment of colorectal carcinoma; pharmaceuticals comprising small molecules for the treatment of pancreatic cancer; pharmaceuticals comprising compounds for the treatment of cancer; pharmaceuticals comprising inhibitors for the treatment of cancer; pharmaceuticals for the treatment of solid tumors; pharmaceuticals for the treatment of advanced solid tumors	04/05/2023
MAVTYKA Pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for use in oncology; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for the treatment of bladder cancer; pharmaceutical preparations for the treatment of lung cancer; pharmaceutical preparations for the treatment of renal cancer; pharmaceutical preparations for the treatment of renal cell carcinoma; pharmaceutical preparations for the treatment of squamous cell carcinoma; pharmaceutical preparations for the treatment of head and neck squamous cell carcinoma; pharmaceutical preparations for the treatment of oral cavity squamous cell carcinoma; pharmaceutical preparations for the treatment of colorectal cancer; pharmaceuticals comprising small molecules for the treatment of cancer; pharmaceuticals comprising small molecules for the treatment of bladder cancer; pharmaceuticals comprising small molecules for the treatment of lung cancer; pharmaceuticals comprising small molecules for the treatment of renal cancer; pharmaceuticals comprising small molecules for the treatment of renal cell carcinoma; pharmaceuticals comprising small molecules for the treatment of squamous cell carcinoma; pharmaceuticals comprising small molecules for the treatment of head and neck squamous cell carcinoma; pharmaceuticals comprising small molecules for the treatment of oral cavity squamous cell carcinoma; pharmaceuticals comprising small molecules for the treatment of colorectal cancer; pharmaceutical products for the treatment of cancer; pharmaceutical products for use in oncology; pharmaceutical products for the treatment of infectious diseases; pharmaceutical products for the treatment of bladder cancer; pharmaceutical products for the treatment of lung cancer; pharmaceutical products for the treatment of renal cancer; pharmaceutical products for the treatment of renal cell carcinoma; pharmaceutical products for the treatment of squamous cell carcinoma; pharmaceutical products for the treatment of head and neck squamous cell carcinoma; pharmaceutical products for the treatment of oral cavity squamous cell carcinoma; pharmaceutical products for the treatment of colorectal cancer; pharmaceuticals comprising compounds for the treatment of cancer; pharmaceuticals comprising inhibitors for the treatment of cancer; pharmaceuticals for the treatment of solid tumors	08/23/2022
LIFTYKA Pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for use in oncology; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for the treatment of bladder cancer; pharmaceutical preparations for the treatment of lung cancer; pharmaceutical preparations for the treatment of renal cancer; pharmaceutical preparations for the treatment of renal cell carcinoma; pharmaceutical preparations for the treatment of squamous cell carcinoma; pharmaceutical preparations for the treatment of head and neck squamous cell carcinoma; pharmaceutical preparations for the treatment of oral cavity squamous cell carcinoma; pharmaceutical preparations for the treatment of colorectal cancer; pharmaceuticals comprising small molecules for the treatment of cancer; pharmaceuticals comprising small molecules for the treatment of bladder cancer; pharmaceuticals comprising small molecules for the treatment of lung cancer; pharmaceuticals comprising small molecules for the treatment of renal cancer; pharmaceuticals comprising small molecules for the treatment of renal cell carcinoma; pharmaceuticals comprising small molecules for the treatment of squamous cell carcinoma; pharmaceuticals comprising small molecules for the treatment of head and neck squamous cell carcinoma; pharmaceuticals comprising small molecules for the treatment of oral cavity squamous cell carcinoma; pharmaceuticals comprising small molecules for the treatment of colorectal cancer; pharmaceutical products for the treatment of cancer; pharmaceutical products for use in oncology; pharmaceutical products for the treatment of infectious diseases; pharmaceutical products for the treatment of bladder cancer; pharmaceutical products for the treatment of lung cancer; pharmaceutical products for the treatment of renal cancer; pharmaceutical products for the treatment of renal cell carcinoma; pharmaceutical products for the treatment of squamous cell carcinoma; pharmaceutical products for the treatment of head and neck squamous cell carcinoma; pharmaceutical products for the treatment of oral cavity squamous cell carcinoma; pharmaceutical products for the treatment of colorectal cancer; pharmaceuticals comprising compounds for the treatment of cancer; pharmaceuticals comprising inhibitors for the treatment of cancer; pharmaceuticals for the treatment of solid tumors	08/23/2022

See all trademarks and details in the Full Report.

Market Share of Mirati Therapeutics's Largest Competitors

A competitive analysis shows these companies are in the same general field as Mirati Therapeutics, even though they may not compete head-to-head. These are the largest companies by revenue. However, they may not have the largest market share in this industry if they have diversified into other business lines. The "Competition" section of a business plan or investment memorandum would start by analyzing the information about these companies. Competitive advantage comes from offering better pricing or superior products/service.

Company	Headquarters	Revenue ($ MM)
LEIDOS	Denver, CO	100
NATIONAL TECHNOLOGY & ENGINEERING SOLUTIONS OF SANDIA	Albuquerque, NM	30
INC RESEARCH	Raleigh, NC	27
RESEARCH FOUNDATION FOR STATE UNIVERSITY OF NEW YORK	Albany, NY	17
FLUOR MARINE PROPULSION	West Mifflin, PA	15
SYNEOS HEALTH	Raleigh, NC	13
ILLUMINA	San Diego, CA	12
UT-BATTELLE	Oak Ridge, TN	11
PRA HOLDINGS	Raleigh, NC	11

Nearby Competitors

These companies are similar in business line and location to Mirati Therapeutics. While some companies compete with neighboring businesses for customers, other companies may compete to attract skilled employees.

Company	Headquarters	Revenue ($ MM)
ILLUMINA	San Diego, CA	100
NEUROCRINE BIOSCIENCES	San Diego, CA	23
SANTARUS	San Diego, CA	16
HALOZYME THERAPEUTICS	San Diego, CA	15
MIRATI THERAPEUTICS	San Diego, CA	12
FATE THERAPEUTICS	San Diego, CA	11

Future Competition: Mirati Therapeutics's Fastest Growing Competitors

These companies are in the same general field as Mirati Therapeutics and are rapidly expanding. Companies may grow organically or through acquisition. In some cases apparently high growth rates may be caused by data that weren't available in previous years.

Company	Revenue ($ MM)